FactaeThe Factual News

Clesrovimab approved in Europe to protect infants from RSV

Clesrovimab receives European marketing authorization to prevent respiratory syncytial virus infections in infants.

Published 16sem1 sourceImportantupdated 2sem
Lire en français
20s

The fact

This treatment offers protection against a major viral disease affecting very young children during winter.

The approval provides access to this monoclonal antibody to reduce neonatal respiratory complications.

Click the link to read an article on the topic:
Explore this topic
What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.
Follow topic →
Auto-synthesis from 1 media source · identified on May 6, 2026
Back to home
Discover

Read more

All sante →